Fe(III)-beta-ketoamide complexes for iron deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron deficiency treatments, particularly using Fe(II) salts, are plagued by high side effects such as oxidative stress due to the formation of reactive oxygen species, and existing iron complexes often have complex structures and synthesis challenges that hinder effective oral administration.
Innovation Solution
Development of iron(III)-β-ketoamide complex compounds with bidentate β-ketoamide ligands that facilitate direct uptake into intestinal cells, releasing iron to ferritin or transferrin without forming free iron ions, thus minimizing oxidative stress and side effects, and are designed for oral administration with simple synthesis processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Fe(II) salts are used for iron deficiency treatment, then iron supplementation is achieved, but oxidative stress and side effects occur due to formation of reactive oxygen species
Solution Approach 1:
The patent employs Fe(III) complex compounds with β-diketonate and amino acid ligands as intermediary substances that deliver iron to the body without causing oxidative stress. These complexes act as mediators between iron supplementation and safe delivery, preventing the formation of reactive oxygen species while maintaining iron absorption. The specific coordination chemistry of Fe(III) with these ligands creates a stable yet bioavailable form of iron that bypasses the harmful effects of Fe(II) salts.
Solution Approach 2:
The invention changes the oxidation state parameter from Fe(II) to Fe(III) and modifies the ligand environment to eliminate harmful effects. By transitioning from ferrous salts to ferric complexes with specific β-diketonate and amino acid ligands, the patent alters the chemical parameters to achieve iron supplementation without oxidative stress. The specific coordination geometry and ligand field strength are optimized to prevent reactive oxygen species formation.
2Reliability
If existing iron complexes are used, then iron delivery is improved, but complex structures and synthesis challenges hinder effective oral administration
Solution Approach 1:
The patent segments the iron delivery system into distinct functional components: Fe(III) center, β-diketonate ligands, and amino acid ligands. This segmentation allows each component to be optimized independently for stability, bioavailability, and ease of synthesis. The modular nature of these coordination complexes simplifies the overall structure while maintaining reliable iron delivery, making oral administration feasible.
Solution Approach 2:
The invention employs simple, readily available β-diketonate and amino acid ligands that can be synthesized through straightforward processes. These ligands form stable but not overly complex complexes that are easy to manufacture. The simplicity of the molecular structures and synthesis routes makes these iron complexes suitable for oral medication production, avoiding the need for complex manufacturing processes.
3Quantity of substance
If Fe(III) compounds are dissolved in stomach acid for absorption, then iron becomes available for uptake, but the absorption process requires reduction to Fe(II) which may cause side effects
Solution Approach 1:
Instead of reducing Fe(III) to Fe(II) for absorption as in conventional approaches, the patent inverts the approach by using Fe(III) complexes that are directly absorbed in the ferric state. The β-diketonate and amino acid ligands protect the Fe(III) center during gastric passage and facilitate direct uptake by intestinal cells, eliminating the need for reduction to Fe(II) and the associated side effects.
Solution Approach 2:
The Fe(III) complexes with β-diketonate and amino acid ligands serve as intermediaries that enable direct absorption without reduction. These complexes act as mediators between dietary iron and intestinal uptake mechanisms, allowing ferric iron to be absorbed directly while protecting against the harmful effects of reduction to ferrous state and subsequent oxidative stress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iron(III)-β-ketoamide complex compounds exhibit high iron uptake, rapid therapeutic effects, and significantly reduced side effects compared to traditional Fe(II) salts, maintaining stability across various pH ranges and being suitable for oral medicament formulation.
Implementation Method 1
iron(III)-β-ketoamide complex compounds with bidentate β-ketoamide ligands that facilitate direct uptake into intestinal cells, releasing iron to ferritin or transferrin without forming free iron ions
Implementation Method 2
releasing iron to ferritin or transferrin without forming free iron ions, thus minimizing oxidative stress and side effects
Data Source
AI summary
The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.